多西他赛治疗老年低分化胃癌的疗效及安全性

Efficacy and Safety of Docetaxel in the Treatment of Elderly Patients With Low Differentiated Gastric Cancer

目的探讨多西他赛为主的两药与三药方案治疗老年低分化胃癌的疗效及安全性。方法抽取至2015年1月—2017年1月我院就诊的老年低分化胃癌患者36例,对常规组采取多西他赛+奥沙利铂+替吉奥化疗,对实验组采取多西他赛+奥沙利铂化疗,对比两组的临床疗效与安全性。结果实验组与常规组的客观缓解率、临床获益率对比,差异无统计学意义(P>0.05);治疗前后两组的KPS评分对比,差异无统计学意义(P>0.05);实验组患者治疗后的不良反应发生率低于常规组,差异具有统计学意义(P<0.05)。结论对老年低分化胃癌患者采取多西他赛为主的两药与三药方案临床疗效相当,且两药治疗的安全性更高。

Objective To explore the efficacy and safety of two drugs and three drug regimens for the treatment of senile low differentiation gastric cancer.Methods36cases of elderly patients with low differentiated gastric cancer were selected from January2015to January2017in our hospital.The routine group was treated with docetaxel+oxaliplatin+S-1chemotherapy,the experimental group was treated with docetaxel+oxaliplatin,and the clinical efficacy and safety of the two groups were compared.Results The difference of objective remission rate and clinical benefit rate between the experimental group and the routine group was not statistically significant(P>0.05).The difference of KPS scores between the two groups before and after treatment was not statistically significant(P>0.05).The incidence of adverse reactions of the patients in the experimental group was lower than that of the conventional group,and the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of docetaxel in the patients with low differentiation of gastric cancer is comparable to that of the three drug regimens,and the safety of the two drugs is higher.